Peptide news, FDA decisions, and research updates

Reviewed by the Rite Aid Health Team

Follow FDA decisions, compounding status, safety reviews, and clinical research by substance, including which peptides are affected, what changes in practice, and the next official step.

Get the Free Peptide Tracking Toolkit

News + many more

Explore the guide, then keep the details you verify in the Excel workbook.

Excel workbook

11 worksheets for vials, schedules, labs, storage, and more.

PDF guide

Review providers, products, documents, storage, and travel.

Get the free toolkit

Free download

Useful before or after you start

Before you start, compare the details that matter and build a focused question list.
Already using peptides? Keep vials, administration, sites, wellness notes, labs, storage, and travel together.
Separate your schedule from what actually happened, so important dates are easier to spot.
Keep your private working copy on your own device.

Confirm your email to receive both downloads and your personal 20% off coupon.

Almost done

We sent the first email to .

Confirm your email to get the toolkit and your 20% off coupon.

We also sent a verification text. Reply YES to confirm your phone number.

1

Confirm your email

Open the first email and click the confirmation link.
2

Only after step 1

Then the toolkit arrives

We email your Excel workbook and PDF guide right away. Your personal 20% off coupon follows when ordering opens.

The first email should arrive within a minute. Do not see it? Check spam or promotions.

Tell us where to send it

Free, no spam, only peptide news that matters. Unsubscribe anytime.

I agree to receive the toolkit, my personal coupon, peptide news, and offers by email and, if I provide a phone number, by text.

A National Cancer Institute researcher prepares genetic samples in a laboratory.

July 25, 2026

What the July 2026 FDA peptide panel vote means

On July 23 and 24, 2026, an FDA advisory committee recommended six peptide-related substances for the Section 503A Bulks List and voted against emideltide.

Read the full update

A National Cancer Institute technician reviews cellular data at a microscope.

April 23, 2026

What changed when peptide nominations left FDA Category 2

In April 2026, several peptide nominations moved from FDA’s active Category 2 table to its withdrawn-nomination table. Their nominations ended in that form, while their bulks-list and drug-approval status stayed unchanged.

Read the full update

For general education only — not medical advice or a treatment recommendation. Peptides are not a substitute for care from a licensed provider. Talk to a qualified healthcare professional before you start, stop, or change any peptide, medication, or supplement.